Insights on Lung Cancer Treatment
What Doctors Expect from an Impactful Webinar
Search Menu

Neoadjuvant Chemotherapy and Ipilimumab For Stage II-IIIA Non-Small Cell Lung Cancer

Objective of this Therapy Area Insight Immune therapy is increasingly becoming an effective treatment for non-small cell lung cancer (NSCLC). The Objective of this study is to determine the percentage of early stage NSCLC patients with detectable circulating T cells specific against tumor-associated antigen (TAA) after receiving platinum based neoadjuvant chemotherapy plus ipilimumab before surgery.…

What Doctors Expect from an Impactful Webinar

HCP Preference on Effectiveness of COVID-19 Vaccine

Popular Discussions
Charles Meyer
1 minute read

Objective of this Therapy Area Insight

Immune therapy is increasingly becoming an effective treatment for non-small cell lung cancer (NSCLC). The Objective of this study is to determine the percentage of early stage NSCLC patients with detectable circulating T cells specific against tumor-associated antigen (TAA) after receiving platinum based neoadjuvant chemotherapy plus ipilimumab before surgery.

small cell lung cancer

TOP1201 Clinical Trial

‘TOP1201’ an open label phase II trial was conducted to evaluate the safety and feasibility of neoadjuvant chemotherapy plus ipilimumab followed by surgery as a treatment strategy for stage II-IIIA non-small cell lung cancer.

Intervention

Adjuvant (Post-Surgery): Ipilimumab

10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative

Neoadjuvant (Pre-Surgery)

10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours, followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1

Paclitaxel, Cisplatin, Carboplatin Neoadjuvant (Pre-Surgery)

Paclitaxel, Cisplatin, Carboplatin Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours, followed by Cisplatin 75mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1

Results

Conclusion – The use of neoadjuvant ipilimumab with chemotherapy before surgical resection of stageII-IIIA NSCLC was found to be safe and feasible

    Exclusive Insights with Our Pharma Marketing Expertise

    Recognized for authoritative insights, our team’s guidance elevates pharma marketing. Act swiftly— consultation availability this quarter is limited. Secure your access to our solutions for effective HCP engagement



    Based on our initial conversation, we'll prepare insights and strategic advice tailored specifically for your pharma marketing endeavors.

    Author

    Charles Meyer

    HealthTech entrepreneur driven by a lifelong passion to build game-changing products to improve global healthcare. MedSynapse is an online community of doctors that helps them connect and collaborate with each other for a better patient outcome.
    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Related Posts
    Therapy Insights: Orthopaedics – Making No Bones About It

    Orthopaedics – Making No Bones About It

    Dive deep into into what goes inside orthopaedician's brain. This therapy area insights sums up their preference in terms of content, discussions, and debates. The insight report is based on the online behaviour of orthopedician members of MedSynapse platform.

    Navigating the Future of Atopic Dermatitis Care: Insights from MedSynapse

    In the ever-evolving field of dermatology, Atopic Dermatitis (AD) stands out as a condition demanding nuanced care and a deep understanding of its multifaceted nature. Healthcare professionals (HCPs) are on a continual quest to refine their management techniques, diagnosis processes, and patient education methods. Drawing from an extensive analysis of conversations among dermatologists, pediatricians, allergists,…
    Rare Disease - Therapy Area Insight

    Looking for Zebras: Therapy Insights on Rare Diseases

    It is often said that when you hear hoofbeats, think horses, not zebras. However, once you have ruled out horses, zebras are the most likely conclusion. That is definitely true in the case of rare diseases. These conditions not only require early screening and diagnosis, but also adequate information, medical expertise, and access to the…
    Subscribe to MedSynapse Insights News Letter

    Never miss an insight from us. We'll email you when new articles are published on this topic.

    Open chat
    Hello 👋
    Can we help you?